膀胱过动症治疗市场- 依病情类型（[神经源性、特发性]、治疗类型（药物治疗[抗胆碱能、Beta-3 肾上腺素受体激动剂]、肉毒桿菌治疗、神经调节））、年龄组（31-50、51-60） - 全球预测（2024 - 2032）

在治疗方案的进步和研发力度的推动下，全球膀胱过动症治疗市场在 2024 年至 2032 年间将达到 4.3% 的复合年增长率。药物创新，例如新药和先进神经调节技术的开发，为患者提供了更有效和多样化的治疗选择。对 OAB 根本原因和管理的持续研究推动了改进疗法和干预措施的创建。这种持续的进步提高了治疗效果，扩大了行业产品范围，并满足了对有效 OAB 解决方案不断增长的需求。

例如，2024 年 7 月，药品和保健品监管局 (MHRA) 批准 vibegron (Obgemsa) 用于治疗成年患者膀胱过动症候群 (OAB) 症状。这项进展引入了一种新的治疗选择，扩大了可用于治疗 OAB 症状的治疗范围。此次批准强调了该领域持续的创新，有可能透过满足有效新疗法的需求来推动市场成长。它也反映了对解决和改善膀胱过动症患者护理的更广泛承诺。

膀胱过动症治疗行业根据病情类型、治疗类型、年龄层和地区进行划分。

由于老年人此病的盛行率较高，到 2032 年，60 岁以上族群将大幅增加。与年龄相关的膀胱功能变化和相关健康问题发生率的增加导致对有效治疗方案的更大需求。随着人口的增长，针对老年人群的专门治疗的需求日益增加。这一趋势凸显了 60 岁及以上年龄组靶向膀胱过动症治疗的巨大市场潜力。

在有效管理症状的创新方法的推动下，神经调节领域到 2032 年将取得显着进展。骶神经刺激和经皮胫神经刺激等技术可透过调节参与膀胱控制的神经活动来提供有针对性的缓解。这些先进的疗法提供了重要的好处，包括与传统疗法相比减少了副作用。随着对微创和有效解决方案的需求不断增长，神经调节在提供个人化、持久缓解方面的作用推动了其在行业中的主导地位。

由于其先进的医疗基础设施和该疾病的高盛行率，欧洲膀胱过动症治疗市场到 2032 年将保持适度的复合年增长率。该地区强大的医学研究能力和对创新疗法的大量投资促进了该行业的成长。此外，提高意识和获得专业医疗服务也支持了对有效膀胱过动症治疗的需求。欧洲将先进的医疗保健系统和积极的研究相结合，使其成为全球膀胱过动症治疗行业的关键贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 膀胱过动症盛行率上升
    • 人口老化加剧
    • 增加研究投资和活动
    • 提高早期诊断和治疗意识
  • 产业陷阱与挑战
    • 与药物和治疗相关的不良反应
• 成长潜力分析
• 管道分析
• 监管环境
• 波特分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按条件类型，2021 - 2032 年

• 主要趋势
• 神经源性膀胱过动症
• 特发性膀胱过动症

第 6 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 药物治疗
  • 抗胆碱药
  • Beta-3 肾上腺素受体激动剂
• 肉毒桿菌治疗
• 神经调节
• 其他治疗类型

第 7 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• 18-30日
• 31-50
• 51-60
• 60以上

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc.
• Astellas Pharma Inc.
• Axonics, Inc.
• BlueWind Medical
• Cipla Ltd.
• Endo International plc
• Laborie
• Lupin Ltd.
• Medtronic plc
• Merck & Co.
• Pfizer Inc.
• Sumitomo Pharma America, Inc. (Urovant Sciences)
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd.

Global Overactive Bladder Treatment Market will achieve a 4.3% CAGR between 2024 and 2032, propelled by advancements in treatment options and increased research and development. Innovations in pharmaceuticals, such as the development of new medications and advanced neuromodulation techniques, provide patients with more effective and diverse treatment choices. Ongoing research into the underlying causes and management of OAB fuels the creation of improved therapies and interventions. This continuous progress enhances treatment efficacy, expands industry offerings, and meets the growing demand for effective OAB solutions.

For instance, in July 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved vibegron (Obgemsa) for treating overactive bladder syndrome (OAB) symptoms in adult patients. This development introduces a new therapeutic option, enhancing the range of treatments available for managing OAB symptoms. The approval underscores ongoing innovation in the field, potentially driving market growth by meeting the demand for effective new treatments. It also reflects a broader commitment to addressing and improving care for patients with overactive bladder.

The overactive bladder treatment industry is divided based on the condition type, treatment type, age group, and region.

The 60 above segment will see a considerable surge by 2032, attributed to the higher prevalence of the condition among older adults. Age-related changes in bladder function and an increased incidence of related health issues contribute to a greater demand for effective treatment options. As this demographic grows, the need for specialized therapies tailored to the older population intensifies. This trend highlights the significant market potential within the 60 and above age group for targeted overactive bladder treatments.

The neuromodulation segment will garner notable gains by 2032, driven by its innovative approach to managing symptoms effectively. Techniques such as sacral nerve stimulation and percutaneous tibial nerve stimulation offer targeted relief by modulating nerve activity involved in bladder control. These advanced therapies provide vital benefits, including reduced side effects compared to traditional treatments. As demand for minimally invasive and effective solutions grows, neuromodulation's role in offering personalized, long-lasting relief drives its dominance in the industry.

Europe overactive bladder treatment market will secure a moderate CAGR through 2032, owing to its advanced healthcare infrastructure and high prevalence of the condition. The region's robust medical research capabilities and substantial investment in innovative treatments contribute to industry growth. Additionally, increasing awareness and access to specialized healthcare services support the demand for effective overactive bladder therapies. Europe's combination of sophisticated healthcare systems and active research makes it a key contributor to the global overactive bladder treatment industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of overactive bladder
    • 3.2.1.2 Growing aging population
    • 3.2.1.3 Increasing research investments and activities
    • 3.2.1.4 Growing awareness for early diagnosis and treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects associated with medications and treatment
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porters analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Condition Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Neurogenic bladder overactivity
• 5.3 Idiopathic bladder overactivity

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug therapy
  • 6.2.1 Anticholinergics
  • 6.2.2 Beta-3 adrenoceptor agonists
• 6.3 Botox treatment
• 6.4 Neuromodulation
• 6.5 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 18-30
• 7.3 31-50
• 7.4 51-60
• 7.5 60 above

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Astellas Pharma Inc.
• 9.3 Axonics, Inc.
• 9.4 BlueWind Medical
• 9.5 Cipla Ltd.
• 9.6 Endo International plc
• 9.7 Laborie
• 9.8 Lupin Ltd.
• 9.9 Medtronic plc
• 9.10 Merck & Co.
• 9.11 Pfizer Inc.
• 9.12 Sumitomo Pharma America, Inc. (Urovant Sciences)
• 9.13 Teva Pharmaceutical Industries Ltd.
• 9.14 Viatris Inc.
• 9.15 Zydus Lifesciences Ltd.